ATE518534T1 - Stabile orale pharmazeutische zusammensetzung mit thyroidhormonrezeptoragonisten - Google Patents

Stabile orale pharmazeutische zusammensetzung mit thyroidhormonrezeptoragonisten

Info

Publication number
ATE518534T1
ATE518534T1 AT07723634T AT07723634T ATE518534T1 AT E518534 T1 ATE518534 T1 AT E518534T1 AT 07723634 T AT07723634 T AT 07723634T AT 07723634 T AT07723634 T AT 07723634T AT E518534 T1 ATE518534 T1 AT E518534T1
Authority
AT
Austria
Prior art keywords
hormone receptor
thyroid hormone
pharmaceutical composition
composition containing
receptor agonists
Prior art date
Application number
AT07723634T
Other languages
English (en)
Inventor
Neeraj Garg
Venkatramana M Rao
Rajesh Gandhi
William N Washburn
Konrad Koehler
Johan Malm
Original Assignee
Karobio Ab
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karobio Ab, Bristol Myers Squibb Co filed Critical Karobio Ab
Application granted granted Critical
Publication of ATE518534T1 publication Critical patent/ATE518534T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07723634T 2006-03-28 2007-03-27 Stabile orale pharmazeutische zusammensetzung mit thyroidhormonrezeptoragonisten ATE518534T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0606212.9A GB0606212D0 (en) 2006-03-28 2006-03-28 Pharmaceutical compositions
PCT/EP2007/002688 WO2007110226A1 (en) 2006-03-28 2007-03-27 Stable oral pharmaceutical composition containing thyroid hormone receptor agonists

Publications (1)

Publication Number Publication Date
ATE518534T1 true ATE518534T1 (de) 2011-08-15

Family

ID=36424743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07723634T ATE518534T1 (de) 2006-03-28 2007-03-27 Stabile orale pharmazeutische zusammensetzung mit thyroidhormonrezeptoragonisten

Country Status (20)

Country Link
US (1) US20090220598A1 (de)
EP (1) EP2004168B1 (de)
JP (1) JP2009531359A (de)
KR (1) KR20090013770A (de)
CN (1) CN101426488B (de)
AT (1) ATE518534T1 (de)
AU (1) AU2007229626A1 (de)
BR (1) BRPI0709688A2 (de)
CA (1) CA2642880A1 (de)
DK (1) DK2004168T3 (de)
ES (1) ES2369674T3 (de)
GB (1) GB0606212D0 (de)
MX (1) MX2008012385A (de)
NO (1) NO20083605L (de)
NZ (1) NZ570689A (de)
PL (1) PL2004168T3 (de)
PT (1) PT2004168E (de)
RU (1) RU2450810C2 (de)
WO (1) WO2007110226A1 (de)
ZA (1) ZA200807597B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0724478D0 (en) * 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2609910A1 (de) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Formulierungen für Eprotirome
CN106727453B (zh) * 2017-01-13 2019-04-26 鲁东大学 一种化合物在制备治疗甲状腺机能减退症药物中的应用
AU2019397067A1 (en) 2018-12-12 2021-07-22 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020180624A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
IT201900006923A1 (it) * 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
US12466781B2 (en) 2019-11-29 2025-11-11 Autobahn Therapeutics, Inc. Thyromimetics
WO2021257851A1 (en) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimetics
US12590072B2 (en) 2020-06-17 2026-03-31 Autobahn Therapeutics, Inc. Thyromimetics
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (de) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitoren der expression und/oder funktion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
US5849337A (en) * 1997-06-27 1998-12-15 Gusty Winds Corporation Method of enhancing magnesium absorption and prevention of atherosclerosis
ES2242723T3 (es) * 2000-02-17 2005-11-16 Bristol-Myers Squibb Company Ligandos derivados de anilina para el receptor de la tiroides .
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
CA2440190A1 (en) * 2001-02-15 2003-08-28 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
ITMI20011401A1 (it) * 2001-07-02 2003-01-02 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei
JP2006507223A (ja) * 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常疾患の治療方法
GB0215978D0 (en) * 2002-07-10 2002-08-21 Karobio Ab Novel compounds
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system

Also Published As

Publication number Publication date
MX2008012385A (es) 2009-03-02
CN101426488A (zh) 2009-05-06
WO2007110226A1 (en) 2007-10-04
PL2004168T3 (pl) 2012-01-31
DK2004168T3 (da) 2011-10-31
EP2004168A1 (de) 2008-12-24
GB0606212D0 (en) 2006-05-10
KR20090013770A (ko) 2009-02-05
ES2369674T3 (es) 2011-12-02
NZ570689A (en) 2011-12-22
PT2004168E (pt) 2011-10-24
CA2642880A1 (en) 2007-10-04
US20090220598A1 (en) 2009-09-03
BRPI0709688A2 (pt) 2011-07-19
RU2008142524A (ru) 2010-05-10
RU2450810C2 (ru) 2012-05-20
HK1126404A1 (en) 2009-09-04
JP2009531359A (ja) 2009-09-03
EP2004168B1 (de) 2011-08-03
CN101426488B (zh) 2012-03-21
NO20083605L (no) 2008-11-07
ZA200807597B (en) 2009-06-24
AU2007229626A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
ATE518534T1 (de) Stabile orale pharmazeutische zusammensetzung mit thyroidhormonrezeptoragonisten
MX2010007150A (es) Formulaciones del factor de von-willebrand recombinante.
BRPI0821128A2 (pt) Composição farmacêuticas
WO2010048275A3 (en) Lyophilized recombinant vwf formulations
CL2007001869A1 (es) Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
MX384206B (es) Formulaciones de inhibidores de dpp iv
CO6290631A2 (es) Composición oral que contiene amino ácidos y un agente blanqueador
AU2009215514A9 (en) Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
BRPI0709266B8 (pt) 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
SV2009003221A (es) Composiciones de fenilalquilamino carbamato ref. prd2743svpct
UY30214A1 (es) Modificaciones de ( 5s) -5-(4-(5-cloro-piridin--2-iloxi)-piperidina-1-sulfonilmetil)-5-metil-imidazolidina-2,4-diona, procesos para su preparacion, composiciones que los contengan y aplicaciones.
SG158091A1 (en) Imidazoazepinone compounds
TN2009000510A1 (en) Extended release formulation of nevirapine
WO2009117401A8 (en) Compositions for site-specific delivery of imatinib and methods of use
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
MX2009012370A (es) Formulacion de antraciclina de baja viscosidad.
PT2155255E (pt) Composições que incluem um composto hidrofóbico e um conjugado de poliaminoácido
NO20081721L (no) Stabil fast formulering av sertindol
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
DE602008003788D1 (de) Neuartige rar-rezeptoragonisten-liganden und deren verwendung in der humanmedizin und kosmetik
GEP20135819B (en) 3-(2,2,2-trimethylhydrazinium) propionate dihydrate composition of local administration
MX2012000113A (es) Compuestos alcoxi-carbonil-amino-alquinil-adenosina y derivados de los mismos como agonistas a2ar.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2004168

Country of ref document: EP